Rezpegaldesleukin, an investigational interleukin-pathway agonist, demonstrated efficacy and safety for people with moderate ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

GLP-1 drugs, which have seen widespread success, have been linked to a number of cases of pancreatitis in the UK, which have ...

According to the National Family Health Survey-5 (2019–21), 24% of Indian women and 23% of Indian men are either overweight ...

BMO Capital Markets downgraded Verve Therapeutics to Market perform, saying Eli Lilly’s agreement to buy the gene-editing specialist leaves limited room for the stock to rise before the transaction is ...

Rezpeg's promising Phase 2b data makes Nektar Therapeutics a strong contender in the AD market. Click here to read an ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...

The Vanguard Growth ETF ( VUG 0.85%) doesn't just beat the market -- it demolishes it. A $10,000 investment at its 2004 ...

Eli Lillys Mounjaro KwikPen gains approval in India, targeting diabetes and obesity with its dual-action formula for weight ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Lilly King Gets One More Win at Indy Summer Cup; Regan Smith Drops 56.5 100 Fly Soon-to-be retired Lilly King got one more ...